Revised response criteria for malignant lymphoma. - Wikidata - wikimedia - TriplyDB

Revised response criteria for malignant lymphoma.

Revised response criteria for malignant lymphoma.

http://www.wikidata.org/entity/Q47582438

about

Radiotherapy for advanced-stage aggressive non-Hodgkin lymphoma Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia Anthracycline-containing regimens for treatment of follicular lymphoma in adults Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma Anthracyclines-containing regimens for treatment of follicular lymphoma in adults Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity Bendamustine for patients with B cell lymphoid malignancies Role of rituximab for first-line or relapsed aggressive B-cell lymphoma Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma Rituximab as maintenance therapy for patients with follicular lymphoma Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers The evolving role of response-adapted PET imaging in Hodgkin lymphoma PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas Emerging treatments in Castleman disease - a critical appraisal of siltuximab Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy Next-generation prognostic assessment for diffuse large B-cell lymphoma Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy Management of mantle cell lymphoma in the elderly patient Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies Biomarker validation: common data analysis concerns Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.Advances in the treatment of relapsed or refractory Hodgkin's lymphoma Review of siltuximab in the treatment of multicentric Castleman's disease The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary Mature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern Brazil Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

P2860

Q24187708-3B5612B6-C9A2-43A3-94B8-450BD8BBE998 Q24200280-50759CFC-02FD-4AA4-96C6-1149657798CC Q24201306-496B861D-6780-4CA2-98EC-2C837129CC62 Q24234975-B420D07F-1A6F-4D02-844C-6FF988374831 Q24236087-4EC556E5-7945-4477-93CA-F6FD686528B8 Q24236119-CB3932D2-DCD9-4EA1-819E-FF6299E5C1CF Q24236426-6FCEAD01-9BA3-40F3-9BAD-D9876C7D50C2 Q24236580-3C00C265-EF2B-450A-A38F-9B85D3C805ED Q24236589-E912F6B6-C7F3-4DC8-AD90-477760565F70 Q24241273-39E9D517-EF09-4101-AEE9-305F958C2842 Q24242032-AD6A341B-4748-4B34-9D32-33333200765A Q24599100-8A7DBD55-294E-42EC-B3E2-2D18972525E6 Q24616084-7625EEB0-F40D-4026-8DA8-2EB91AD4AF81 Q24646379-9D20E31F-1A7E-4A83-A4DB-69548B8517E9 Q26750993-34AD1B1A-2BFC-4721-994D-37F5942770F2 Q26752284-E6605552-1A34-48F6-8C3F-B22947B3940F Q26766554-793E0D1C-7218-4B66-9591-F125F771171E Q26781731-23660075-E076-4CE4-B5F6-119443868F4C Q26796428-95B6D7C0-79FC-40FE-9E65-49D122064554 Q26851987-A2BA814D-3795-4640-9AF5-DA9B5FDCDBAB Q26858893-CABFB764-2997-4389-AB26-1CF491C730A3 Q26863624-C8132E4A-3580-4764-B284-426376A567C0 Q26999395-96ECE6CE-94FA-492C-8000-42B4C1214272 Q27009307-6A1DEB96-5BC8-4B23-A3E5-A70EDDF98F53 Q27024057-E0442E97-662B-4226-AC7E-8D2E357A61B2 Q27027445-97758CD4-F99A-4B6E-97C1-5462F7E8207C Q27027579-28F024F5-447B-4C4B-AC3E-144103E021DA Q27314782-C08A901D-B6E1-44CD-BD87-8962F634B8E7 Q27314809-87651E2A-0652-40A8-B501-07EDA274E375 Q27694504-89CB344B-7304-48F4-BA82-A16A7002882B Q28067246-9664A37B-0991-4784-B062-B1560EC22707 Q28072397-C4121F17-C984-4FCF-B82B-5C016E1EC2FE Q28073223-94F7DB22-C2CA-49B6-BC01-3E60966E4320 Q28087748-A698BCC2-060A-4052-A34A-24EF02F31201 Q28088365-4D60A8B2-028C-4512-A28E-784FA518C20F Q28395001-EEB0FBFE-249C-4089-8C81-F6D9C41E5E2A Q28731819-A49A304F-2EE6-4730-A1E0-73BA223CCCE8 Q29048186-E700A32B-550F-42A6-8AAE-BABA5E8011A1 Q29620690-84024F8F-2A0F-40CD-9799-39EF28347915 Q29620717-8BE34D6D-962B-4112-9BFC-DDD8B11D1CDD

P2860

Revised response criteria for malignant lymphoma.

http://www.wikidata.org/entity/Q47582438

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Revised response criteria for malignant lymphoma.

@en

Revised response criteria for malignant lymphoma.

@nl

type

label

Revised response criteria for malignant lymphoma.

@en

Revised response criteria for malignant lymphoma.

@nl

prefLabel

Revised response criteria for malignant lymphoma.

@en

Revised response criteria for malignant lymphoma.

@nl

P1433

Q47582438-F42935C7-1C54-4EA9-A3BD-6234316C2938

P1476

Q47582438-F26020CA-BC1A-4B59-8199-3C5229E87A04

P2093

Q47582438-0DB533D6-6FE5-41A1-8150-17442F16B50B

Q47582438-0FF86712-2896-4ED5-9BC6-5A14B84287AF

Q47582438-38DA2FB9-E9F0-4FE5-95C5-74FE668E6125

Q47582438-3C7A9B10-CBBA-49A5-A2EC-AF0B7FAF9B24

Q47582438-427ED494-2CA8-4737-BB2E-456E0D0A22C0

Q47582438-4D3376C3-5D66-480E-889A-E4E4D6ACBE7D

Q47582438-656D323F-D906-44B5-8530-12F537D34871

Q47582438-69BBBE86-6889-421D-93C7-337E7813DE0B

Q47582438-7405AF89-767A-4EEA-B849-A9FDD292E079

Q47582438-806A8565-0909-4CA9-8D6D-249002477115

P304

Q47582438-83A8F9FF-50DD-4E6F-9E5A-018C313847F3

P31

Q47582438-F2E29F42-7C5A-4A18-AC7C-7C464A2D48C1

P356

Q47582438-176B41A3-00B0-4ED3-976C-29D75E2755BE

P407

Q47582438-C6563025-32B4-4519-A1C3-271EBA386283

P433

Q47582438-369DB65C-FEBD-4AD8-9955-A1296D7B4770

P478

Q47582438-D5201150-29FC-4168-B398-B9E7C5A66113

P50

Q47582438-32E0AD2E-2C41-4209-BCCF-35848B40C0E7

Q47582438-B8A2FF00-DF42-4292-A0A3-F33B3CAB2B15

Q47582438-C73F32BE-36CE-4FA0-A54B-406A6BC3032C

Q47582438-F3BAF51C-CF54-44B9-B0A6-3C8817F10913

P577

Q47582438-6733A63E-83D6-4393-857B-94A2D90A947A

P698

Q47582438-B8556079-0AC6-45D9-9ECA-AD3106D5179C

P356

JCO.2006.09.2403

P1433

Journal of Clinical Oncology

P1476

Revised response criteria for malignant lymphoma.

@en

P2093

Anton Hagenbeek

http://www.w3.org/2001/XMLSchema#string

Beate Pfistner

http://www.w3.org/2001/XMLSchema#string

Bertrand Coiffier

http://www.w3.org/2001/XMLSchema#string

Bruce D Cheson

http://www.w3.org/2001/XMLSchema#string

Emanuele Zucca

http://www.w3.org/2001/XMLSchema#string

International Harmonization Project on Lymphoma

http://www.w3.org/2001/XMLSchema#string

Kensei Tobinai

http://www.w3.org/2001/XMLSchema#string

Malik E Juweid

http://www.w3.org/2001/XMLSchema#string

Martin Dreyling

http://www.w3.org/2001/XMLSchema#string

Massimo Federico

http://www.w3.org/2001/XMLSchema#string

P304

579-586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.09.2403

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Joseph M Connors

Randy D Gascoyne

P577

2007-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17242396

http://www.w3.org/2001/XMLSchema#string